Background: MicroRNAs (miRNAs) have been observed to exhibit altered expression patterns in chronic myeloid leukemia (CML). Therefore, this study was aimed to evaluate the clinical importance of miR-126 and miR-122 expression in concert to imatinib response in CML patients. Methods: The present study included 100 CML and 100 healthy subjects. The expression of the 2 miRNAs was performed using TaqMan probe chemistry, and snU6 was used as internal control. Results: The expression of miR-126 and miR-122 was downregulated in CML patients, with a mean fold change ± SD 0.20 ± 0.33 and 0.22 ± 0.37, respectively. While the expression of both miRNAs was analysed before and after imatinib treatment, it was observed that the expression levels of both were increased after imatinib treatment by 26.25-fold (5.33 against 0.20) and 13.95-fold (3.07 against 0.22) and the increase was statistically significant (p #x3c; 0.0001 and p #x3c; 0.0001, respectively). The expression of miR-126 was not conclusive when compared in different clinical stages of the CML disease as it showed a decreased expression in patients with accelerated phase compared to chronic phase (mean fold change = 0.03 and 0.27, respectively), but patients with chronic phase and blastic phase had comparable expression (mean fold change = 0.27 and 0.24, respectively). We also observed an increased expression of both miRNAs after imatinib therapy in each clinical phase. Conclusion: The study concludes that expression of miR-126 and miR-122 increases after imatinib treatment in CML patients and that miR-126 defines the good responders of imatinib therapy.
Oncol Res Treat

中文翻译：

---

miR-126和miR-122表达的调控及伊马替尼治疗对慢性粒细胞白血病患者表达的反应

背景：已观察到 MicroRNAs (miRNAs) 在慢性粒细胞白血病 (CML) 中表现出改变的表达模式。因此，本研究旨在评估 miR-126 和 miR-122 表达对 CML 患者伊马替尼反应的临床重要性。方法：本研究包括 100 名 CML 和 100 名健康受试者。使用 TaqMan 探针化学进行 2 种 miRNA 的表达，并使用 snU6 作为内部对照。结果：miR-126 和 miR-122 的表达在 CML 患者中下调，平均倍数变化分别为 ± SD 0.20 ± 0.33 和 0.22 ± 0.37。虽然在伊马替尼治疗前后对两种 miRNA 的表达进行了分析，但观察到在伊马替尼治疗后两者的表达水平分别增加了 26.25 倍（5.33 对 0.20）和 13.95 倍（3.07 对 0.22），并且增幅为统计显着性（p #x3c；0.0001 和p#x3c; 0.0001，分别）。miR-126 的表达在 CML 疾病的不同临床阶段进行比较时并不是决定性的，因为它在加速期患者中的表达低于慢性期（平均倍数变化分别 = 0.03 和 0.27），但慢性期患者期和急变期具有相当的表达（平均倍数变化分别为 0.27 和 0.24）。我们还观察到在每个临床阶段伊马替尼治疗后两种 miRNA 的表达增加。结论：该研究得出结论，CML 患者接受伊马替尼治疗后 miR-126 和 miR-122 的表达增加，并且 miR-126 定义了伊马替尼治疗的良好反应者。
肿瘤资源治疗